Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlmazov National Medical Research Centre

About this trial

The planned multicenter randomized study is aimed to assess the efficacy and safety of endoscopic pancreatic duct stenting in adult patients with acute pancreatitis. It is planned to include patients with early-stage nonbiliary pancreatitis in the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of acute pancreatitis confirmed on the basis of at least 2 of the 3 diagnostic criteria according to the revised Atlanta classification

Presence of organ failure signs (moderate and severe pancreatitis)

Informed consent of the patient

Disqualifiers

Presence of other indications for endoscopic intervention on the major duodenal papilla (biliary pancreatitis with cholangitis, calculus of the major duodenal papilla, stenosis of the major duodenal papilla, etc.)

Previous surgical interventions on the major duodenal papilla

Diverticula of the major duodenal papilla

Pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Endoscopic pancreatic duct stent placement

    Procedure/Surgery

    Endoscopic pancreatic duct stent placement will be performed with a 5Fr Boston Scientific pancreatic stent (3-4 cm in length) within 24 hours from the randomization procedure. The stent will be removed on the 5th day after installation.

  • Conventional treatment of acute pancreatitis in early phase

    Drug

    Infusion therapy, pain relief, nutritional support and surgical procedure if needed

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Сomparison groupActive comparator 1 intervention
Group B: Study groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Mortality rate

Data will be tabulated and statistically analyzed in terms of percentages

Time frame
From enrollment to the end of treatment at 3 months

Secondary outcomes

1

Incidence of complications associated with endoscopic pancreatic duct stent placement

Frequency of duodenal bleeding, duodenal perforation, unsuccessful major duodenal papilla canulation etc. Data will be tabulated and statistically analyzed in terms of percentages

Time frame
From endoscopic pancreatic duct stent placement to 3 months
2

Rate of different pancreatic necrosis models

Will be evaluated according CT-imaging: Model 1 - volume of pancreatic necrosis \< 30%, or not determined Model 2 - volume of pancreatic necrosis 30-50%, located in the distal pancreatic part Model 3 - volume of pancreatic necrosis 30-50% located in the proximal part Model 4 - volume of pancreatic necrosis 30-50% and more with separation of viable proximal and distal parts (disconnected duct syndrome) Data will be tabulated and statistically analyzed in terms of percentages

Time frame
From enrollment to the 7th day of treatment
3

Average Balthazar computed tomography severity index (0-10)

A scoring system used to assess the severity of acute pancreatitis based on computed tomography scans. Data will be tabulated and statistically analyzed in terms of mean.

Time frame
From enrollment to the 7th day of treatment
4

Average SOFA (Sequential Organ Failure Assessment Score) score (0-24)

Sequential Organ Failure Assessment Score. Data will be tabulated and statistically analyzed in terms of mean

Time frame
From enrollment to the 7th day of treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: